Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16548
Title: | De novo SCN1A pathogenic variants in the GEFS+ spectrum: not always a familial syndrome | Austin Authors: | Myers, Kenneth A;Burgess, Rosemary;Afawi, Zaid;Damiano, John A;Berkovic, Samuel F ;Hildebrand, Michael S ;Scheffer, Ingrid E | Affiliation: | Department of Medicine, Epilepsy Research Centre, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia Department of Pediatrics, Alberta Children's Hospital, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Tel-Aviv University Medical School, Tel-Aviv University, Tel-Aviv, Israel Department of Paediatrics, Royal Children's Hospital, The University of Melbourne, Flemington, Victoria, Australia The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia |
Issue Date: | Feb-2017 | Date: | 2017-01-13 | Publication information: | Epilepsia 2017; 58(2): e26-e30 | Abstract: | Genetic epilepsy with febrile seizures plus (GEFS+) is a familial epilepsy syndrome characterized by heterogeneous phenotypes ranging from mild disorders such as febrile seizures to epileptic encephalopathies (EEs) such as Dravet syndrome (DS). Although DS often occurs with de novo SCN1A pathogenic variants, milder GEFS+ spectrum phenotypes are associated with inherited pathogenic variants. We identified seven cases with non-EE GEFS+ phenotypes and de novo SCN1A pathogenic variants, including a monozygotic twin pair. Febrile seizures plus (FS+) occurred in six patients, five of whom had additional seizure types. The remaining case had childhood-onset temporal lobe epilepsy without known febrile seizures. Although early development was normal in all individuals, three later had learning difficulties, and the twin girls had language impairment and working memory deficits. All cases had SCN1A missense pathogenic variants that were not found in either parent. One pathogenic variant had been reported previously in a case of DS, and the remainder were novel. Our finding of de novo pathogenic variants in mild phenotypes within the GEFS+ spectrum shows that mild GEFS+ is not always inherited. SCN1A screening should be considered in patients with GEFS+ phenotypes because identification of pathogenic variants will influence antiepileptic therapy, and prognostic and genetic counseling. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/16548 | DOI: | 10.1111/epi.13649 | ORCID: | 0000-0002-1121-9513 0000-0003-4580-841X 0000-0002-2311-2174 |
Journal: | Epilepsia | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/28084635 | Type: | Journal Article | Subjects: | SCN1A De novo pathogenic variant Dravet syndrome Febrile seizures Genetic epilepsy with febrile seizures plus |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.